Sequential development of diffuse panbronchiolitis and myasthenia gravis after thymectomy for thymic neoplasm: a case report.
Case report
Diffuse panbronchiolitis
Myasthenia gravis
Thymic neoplasm
Thymoma
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
02 Jul 2024
02 Jul 2024
Historique:
received:
05
03
2024
accepted:
26
06
2024
medline:
3
7
2024
pubmed:
3
7
2024
entrez:
3
7
2024
Statut:
epublish
Résumé
Myasthenia gravis (MG) is the most common paraneoplastic disorder associated with thymic neoplasms. MG can develop after thymectomy, and this condition is referred to post-thymectomy myasthenia gravis (PTMG). Diffuse panbronchiolitis (DPB), is a rare form of bronchiolitis and is largely restricted to East Asia, has been reported in association with thymic neoplasms. Only three cases of combined MG and DPB have been reported in the literature. A 45-year-old Taiwanese woman presented to our hospital with productive cough, rhinorrhea, anosmia, ear fullness, shortness of breath, and weight loss. She had a history of thymoma, and she underwent thymectomy with adjuvant radiotherapy 7 years ago. Chest computed tomography scan revealed diffuse bronchitis and bronchiolitis. DPB was confirmed after video-assisted thoracoscopic surgery lung biopsy, and repeated sputum cultures grew Pseudomonas aeruginosa. She has been on long-term oral azithromycin therapy thereafter. Intravenous antipseudomonal antibiotics, inhaled amikacin, as well as oral levofloxacin were administered. Three months after DPB diagnosis, she developed ptosis, muscle weakness, and hypercapnia requiring the use of noninvasive positive pressure ventilation. MG was diagnosed based on the acetylcholine receptor antibody and repetitive stimulation test results. Her muscle weakness gradually improved after pyridostigmine and corticosteroid therapies. Oral corticosteroids could be tapered off ten months after the diagnosis of MG. She is currently maintained on azithromycin, pyridostigmine, and inhaled amikacin therapies, with intravenous antibiotics administered occasionally during hospitalizations for respiratory infections. To our knowledge, this might be the first case report of sequential development of DPB followed by PTMG. The coexistence of these two disorders poses a therapeutic challenge for balancing infection control for DPB and immunosuppressant therapies for MG.
Sections du résumé
BACKGROUND
BACKGROUND
Myasthenia gravis (MG) is the most common paraneoplastic disorder associated with thymic neoplasms. MG can develop after thymectomy, and this condition is referred to post-thymectomy myasthenia gravis (PTMG). Diffuse panbronchiolitis (DPB), is a rare form of bronchiolitis and is largely restricted to East Asia, has been reported in association with thymic neoplasms. Only three cases of combined MG and DPB have been reported in the literature.
CASE PRESENTATION
METHODS
A 45-year-old Taiwanese woman presented to our hospital with productive cough, rhinorrhea, anosmia, ear fullness, shortness of breath, and weight loss. She had a history of thymoma, and she underwent thymectomy with adjuvant radiotherapy 7 years ago. Chest computed tomography scan revealed diffuse bronchitis and bronchiolitis. DPB was confirmed after video-assisted thoracoscopic surgery lung biopsy, and repeated sputum cultures grew Pseudomonas aeruginosa. She has been on long-term oral azithromycin therapy thereafter. Intravenous antipseudomonal antibiotics, inhaled amikacin, as well as oral levofloxacin were administered. Three months after DPB diagnosis, she developed ptosis, muscle weakness, and hypercapnia requiring the use of noninvasive positive pressure ventilation. MG was diagnosed based on the acetylcholine receptor antibody and repetitive stimulation test results. Her muscle weakness gradually improved after pyridostigmine and corticosteroid therapies. Oral corticosteroids could be tapered off ten months after the diagnosis of MG. She is currently maintained on azithromycin, pyridostigmine, and inhaled amikacin therapies, with intravenous antibiotics administered occasionally during hospitalizations for respiratory infections.
CONCLUSIONS
CONCLUSIONS
To our knowledge, this might be the first case report of sequential development of DPB followed by PTMG. The coexistence of these two disorders poses a therapeutic challenge for balancing infection control for DPB and immunosuppressant therapies for MG.
Identifiants
pubmed: 38956567
doi: 10.1186/s12890-024-03134-2
pii: 10.1186/s12890-024-03134-2
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
310Informations de copyright
© 2024. The Author(s).
Références
Scorsetti M, Leo F, Trama A, D’Angelillo R, Serpico D, Macerelli M, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–50.
doi: 10.1016/j.critrevonc.2016.01.012
pubmed: 26818050
Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12(9):875–84.
doi: 10.1016/j.autrev.2013.03.007
pubmed: 23535159
Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis — autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016;12(5):259–68.
doi: 10.1038/nrneurol.2016.44
pubmed: 27103470
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–36.
doi: 10.1016/S1474-4422(15)00145-3
pubmed: 26376969
Zhou R-Q, Li L-J, Wu Q-C. Refractory post-thymectomy myasthenia gravis with onset at MGFA stage V: a case report. J Cardiothorac Surg. 2022;17(1):115.
doi: 10.1186/s13019-022-01872-0
pubmed: 35551621
pmcid: 9097348
Liu Y, Xu Y, Tian X, Huang H, Hou X, Chen M, et al. Thymic neoplasms patients complicated with bronchiectasis: Case series in a Chinese hospital and literature review. Thorac Cancer. 2019;10(4):791–8.
doi: 10.1111/1759-7714.13000
pubmed: 30758142
pmcid: 6449260
Poletti V, Casoni G, Chilosi M, Zompatori M. Diffuse panbronchiolitis. Eur Respir J. 2006;28(4):862–71.
doi: 10.1183/09031936.06.00131805
pubmed: 17012632
Xu B, Mao Y, Wan X, Chen J, Ye M, Zhan M, et al. Prognostic value of concomitant bronchiectasis in newly diagnosed diffuse panbronchiolitis patients on a maintenance therapy with macrolides. Can Respir J. 2019;2019:4913814.
doi: 10.1155/2019/4913814
pubmed: 30984318
pmcid: 6431487
Sugimoto S, Miyoshi K, Yamane M, Oto T. Lung transplantation for diffuse panbronchiolitis: 5 cases from a single centre. Interact Cardiovasc Thorac Surg. 2016;22(5):679–81.
doi: 10.1093/icvts/ivw008
pubmed: 26888742
pmcid: 4892152
Chijimatsu Y, Nakazato Y, Homma H, Mizuguchi K. A case report of Good syndrome complicated by diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi. 1982;20(7):803–8.
pubmed: 7143832
Okano A, Sato A, Suda T, Suda I, Yasuda K, Iwata M, et al. A case of diffuse panbronchiolitis complicated by malignant thymoma and Sjögren’s syndrome. Nihon Kyobu Shikkan Gakkai Zasshi. 1991;29(2):263–8.
pubmed: 2033900
Akai M, Ishizaki T, Sasaki F, Ameshima S, Shigemori K, Higashi T, et al. Immunodeficiency with thymoma (Good’s syndrome) similar to sino-bronchial syndrome. Nihon Kyobu Shikkan Gakkai Zasshi. 1996;34(7):829–32.
pubmed: 8810767
Liu H, Liu T, Ren H. Clinicopathological analysis of 6 cases of diffuse panbronchiolitis. Zhonghua Bing Li Xue Za Zhi. 2001;30(5):325–7.
pubmed: 11769725
Xie G, Li L, Liu H, Xu K, Zhu Y. Diffuse panbronchiolitis complicated with thymoma: a report of 2 cases with literature review. Chin Med J (Engl). 2003;116(11):1723–7.
pubmed: 14642145
Tsuburai T, Ikehara K, Suzuki S, Shinohara T, Mishima W, Tagawa A, et al. Hypogammaglobulinemia associated with thymoma (Good syndrome) similar to diffuse panbronchiolitis. Nihon Kokyuki Gakkai Zasshi. 2003;41(6):421–5.
pubmed: 12833850
Zhang D, Wang CH, Li Q. Diffuse panbronchiolitis complicated by thymoma: a case report and a review of literature. Zhonghua Jie He He Hu Xi Za Zhi. 2004;27(9):608–10.
pubmed: 15498273
Zhai HFHZ, Jiao YM. Diffuse panbronchiolitis occurred after thymectomy for thymoma: A case report. Chin J Respir Crit Care Med. 2009;18:82–3.
Jadhav S, Joshi JM. Diffuse panbronchiolitis associated with malignant thymoma. Indian J Chest Dis Allied Sci. 2010;52(1):41–2.
pubmed: 20364613
Luo T, Wang L, Fu D, Hu R, Kong C, Chen Y, et al. Good’s syndrome with diffuse panbronchiolitis as the prominent manifestation: A case and literature review. Respirol Case Rep. 2021;9(12):e0873.
doi: 10.1002/rcr2.873
pubmed: 34765226
pmcid: 8573544
Carnevale A, Lucioni E, Daniele MM, Contoli M, Giganti M, Marku B. Diffuse panbronchiolitis as parathymic syndrome in a Caucasian man previously treated for thymoma. Radiol Case Rep. 2021;16(10):3029–33.
doi: 10.1016/j.radcr.2021.07.026
pubmed: 34408804
pmcid: 8361232
Jin ZQC, Chen J. Thymoma with diffuse panbronchiolitis-case report. The 12th National Academic Conference on Respiratory Diseases/Chinese Medical Association Annual Meeting on Respiratory Diseases. 2011.
Ogoshi T, Ishimoto H, Yatera K, Oda K, Akata K, Yamasaki K, et al. A case of good syndrome with pulmonary lesions similar to diffuse panbronchiolitis. Intern Med. 2012;51(9):1087–91.
doi: 10.2169/internalmedicine.51.7028
pubmed: 22576393
Maekawa R, Shibuya H, Hideyama T, Shiio Y. A case of myasthenia gravis with invasive thymoma associated with diffuse panbronchiolitis, alopecia, dysgeusia, cholangitis and myositis. Rinsho Shinkeigaku. 2014;54(9):703–8.
doi: 10.5692/clinicalneurol.54.703
pubmed: 25283823
Rath J, Taborsky M, Moser B, Zulehner G, Weng R, Krenn M, et al. Short-term and sustained clinical response following thymectomy in patients with myasthenia gravis. Eur J Neurol. 2022;29(8):2453–62.
doi: 10.1111/ene.15362
pubmed: 35435305
pmcid: 9541265
Zhang X, Li B, Zou J, Su C, Zhu H, Chen T, et al. Perioperative risk factors for occurrence of myasthenia gravis after thymectomy in patients with thymoma. Interact Cardiovasc Thorac Surg. 2020;31(4):519–26.
doi: 10.1093/icvts/ivaa133
pubmed: 32862219